THE NEXT PARADIGM SHIFT
SHIFTBIO INC.
01. Summary
Cell-Free Nanotherapy Platform Technologies as Revolutionary Regenerative Immunotherapy
SHIFTBIO INC., the leader in transformative regenerative immunotherapy, is steering a paradigm shift in medicine with its groundbreaking Cell-Free Nanotherapy Platform Technologies - Maxisome, InProDel, and Fusosome. Our mission is to breathe new life into areas of medicine previously deemed inoperable, offering innovative, life-altering treatments for patients devoid of options.
We have reimagined the potential of stem cell therapies by engineering powerful regenerative immunotherapeutic nanovesicles derived from mesenchymal stem cells. The resulting therapies eclipse traditional stem cell methods in potency and efficiency while minimizing the current limitations of cell therapies.
Our Maxisome and InProDel technologies have been instrumental in creating SIRP-NV and HIF1α-NV, respectively. These developments are redefining regenerative immune responses, bringing newfound hope to those grappling with acute organ failures. With our pioneering Fusosome technology, we are rewriting the rules of therapeutic delivery, enabling in vivo cell membrane editing and bypassing the endo-lysosomal pathway, a critical stride forward in the field.
Our mission, "Giving New Chance to Life, Cure the Incurables," is driven by our excellent team, including 3 MD-PhD co-founders, as we strive to advance treatments for rare and untreatable diseases.
02.Founder
Won-Yong Lee, Co-Founder & Chairperson of SHIFTBIO INC.
- MD. From Seoul National University School of Medicine
- Ph.D. from Sungkyunkwan University
- Otolaryngologist at Samsung Medical Center
- Assistant professor at Busan National University
Gi-Hoon Nam, Co-Founder & CEO of SHIFTBIO INC.
- MD. From Korea University School of Medicine
- Ph.D. from KU-KIST Graduate School
- Professor at Korea University College of Medicine
- Research on Cancer Immunotherapy and EV engineering at KIST, the Dana-Faber Cancer Institute and Harvard Medical School